compound tirzepatide ban update FDA Allows Compounded During Shortage Review compound tirzepatide shortage Terrible predictions

Get that right

Engineered agonists that bias signaling toward specific downstream effectors are an active research frontier, with the goal of isolating the therapeutically relevant signaling from the full receptor-activation profile

doi: 10.1038/d41573-022-00001-9

doi: 10.1007/s00125-016-3874-y 15 PsilopanagiotiANikouSLogothetiSArbiMChartoumpekisDVPapadakiH

Cancers (Basel) 11(10):E1610 Rashida Gnanaprakasam JN, Wu R, Wang R (2018) Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity

however, there is also no evidence that they impair the efficacy of the mTOR inhibitor